1998
DOI: 10.1128/jcm.36.1.294-295.1998
|View full text |Cite
|
Sign up to set email alerts
|

Premarket Evaluation of a Commercial Glycoprotein G-Based Enzyme Immunoassay for Herpes Simplex Virus Type-Specific Antibodies

Abstract: A new commercial glycoprotein G-based enzyme immunoassay (gG-EIA) was compared with Western blotting (WB) for detection of herpes simplex virus type 1 (HSV-1) or HSV-2 type-specific antibodies in 193 serum samples. Sensitivity for HSV-1 was 95%; specificity was 96%. Sensitivity for HSV-2 was 98%; specificity was 97%. Twelve of 13 serum samples with equivocal gG-EIA results were serotyped by WB.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
17
0

Year Published

2000
2000
2009
2009

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 107 publications
(19 citation statements)
references
References 21 publications
(22 reference statements)
2
17
0
Order By: Relevance
“…Initial HIV screening used Genetic Systems ELISA (Redmond, WA, USA); this was confirmed using BIO‐RAD NOVAPATH Western blot (Hercules, CA, USA). Hepatitis B tests assayed surface antigen (AUS ZYME monoclonal), core antibody (CORE ZYME) and surface antibody (AUSAB EIA) (all from Abbott, Abbott Park, IL, USA). Subjects were coded as having been infected at some time if they were positive for any of these markers except if they were positive only on surface antibody (which was treated as putative evidence of vaccination—in which case, like subjects with no data, they were excluded from the denominator in estimates of percentage ever infected). Hepatitis C antibody was measured using the Abbott EIA screening assay and confirmed by Ortho Diagnostics RIBA‐2 (Raritan, NJ, USA). Herpes simplex virus type 2 antibody was determined using Gull Laboratories (Salt Lake City, UT, USA) glycoprotein type‐specific ELISA test (Ashley et al . 1998).…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Initial HIV screening used Genetic Systems ELISA (Redmond, WA, USA); this was confirmed using BIO‐RAD NOVAPATH Western blot (Hercules, CA, USA). Hepatitis B tests assayed surface antigen (AUS ZYME monoclonal), core antibody (CORE ZYME) and surface antibody (AUSAB EIA) (all from Abbott, Abbott Park, IL, USA). Subjects were coded as having been infected at some time if they were positive for any of these markers except if they were positive only on surface antibody (which was treated as putative evidence of vaccination—in which case, like subjects with no data, they were excluded from the denominator in estimates of percentage ever infected). Hepatitis C antibody was measured using the Abbott EIA screening assay and confirmed by Ortho Diagnostics RIBA‐2 (Raritan, NJ, USA). Herpes simplex virus type 2 antibody was determined using Gull Laboratories (Salt Lake City, UT, USA) glycoprotein type‐specific ELISA test (Ashley et al . 1998).…”
Section: Methodsmentioning
confidence: 99%
“…Herpes simplex virus type 2 antibody was determined using Gull Laboratories (Salt Lake City, UT, USA) glycoprotein type‐specific ELISA test (Ashley et al . 1998).…”
Section: Methodsmentioning
confidence: 99%
“…31 The availability of accurate, type-specific serologic tests for HSV-2 is likely to identify many people with previously unrecognized infection. 32,33 Counseling to encourage consistent condom use is appropriate for these patients, especially for men with HSV-2 infection.…”
Section: Commentmentioning
confidence: 99%
“…Several seroassays based on gG‐2 as the diagnostic antigen have been established and proved to be useful diagnostic tools, allowing sensitive and specific detection of HSV‐2 specific antibodies in human sera. Their high sensitivity (92–98%) and specificity (94–97%) have been recorded in several studies (20–23). Recently, type‐specific ELISA using gG‐2 was superior in giving the real prevalence of HSV‐2 than non‐specific ELISA among population at risk of HSV infection (24).…”
Section: Discussionmentioning
confidence: 84%